Meeting
2017 Genitourinary Cancers Symposium
Correlation of insulin-receptor expression with efficacy of axitinib in patients with advanced renal cell carcinoma.
Authors
Masayuki Takahashi
Department of Urology, Tokushima University Graduate School, Tokushima, Japan
Masayuki Takahashi , Kei Daizumoto , Megumi Tsuda , Yoshito Kusuhara , Hidehisa Mori , Terumichi Shintani , Tomoya Fukawa , Yasuyo Yamamoto , Kunihisa Yamaguchi , Tomoharu Fukumori , Hiroomi Kanayama
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Penile, Urethral, and Testicular Cancers; Renal Cell Cancer
Track
Renal Cell Cancer,Penile, Urethral, and Testicular Cancers
Sub Track
Renal Cell Cancer
Citation
J Clin Oncol 35, 2017 (suppl 6S; abstract 442)
DOI
10.1200/JCO.2017.35.6_suppl.442
Abstract #
442
Poster Bd #
D5
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Efficacy, safety, and tolerability of tivozanib (TIVO) in heavily pretreated patients (pts) with advanced clear-cell renal cell carcinoma (ccRCC).
First Author: Andrew Johns
Poster
2023 ASCO Genitourinary Cancers Symposium
Real-world survival outcomes of patients (pts) treated with 6-weekly pembrolizumab 400mg (pem6w) plus axitinib (axi) for advanced renal cell carcinoma (aRCC).
First Author: Sonam Ansel
Poster
2022 ASCO Annual Meeting
Efficacy of immune checkpoint inhibitor (ICI) rechallenge in advanced melanoma patients responders to a first course of ICI: A multicenter, national, retrospective study of the French group of skin cancers (GCC).
First Author: Charlee Nardin
Poster
2021 ASCO Annual Meeting
Efficacy outcomes of nivolumab + cabozantinib versus pembrolizumab + axitinib in patients with advanced renal cell carcinoma (aRCC): Matching-adjusted indirect comparison (MAIC).
First Author: Bradley Alexander McGregor